COMP <GO>
DXCM vs RMD // EV/EBITDA & P/E VALUATION
DexCom Inc. (NASDAQ) VS. ResMed Inc. (NYSE) • 15-METRIC TALLY: DXCM 3
— RMD 10
▲ EV/EBITDA & P/E VALUATION LEADER: RMD
LAST: $82.29 (+2.95%) • MKT CAP: $30.16B
valuation
25.2x
LAST: $229.94 (-9.05%) • MKT CAP: $35.56B
valuation
19.9x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (DXCM VS. RMD)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | DXCM | RMD | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 60.10% | 59.40% | +0.70 | DXCM | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 21.60% | 22.90% | -1.30 | RMD | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 25.2x | 19.9x | +5.30 | RMD | /valuation <GO> |
| Free Cash Flow Yield | 3.57% | 4.67% | -1.10 | RMD | /fcf-yield <GO> |
| Operating Margin | 19.60% | 32.70% | -13.10 | RMD | /operating-margins <GO> |
| Net Profit Margin | 17.90% | 27.20% | -9.30 | RMD | /net-margins <GO> |
| Revenue Growth (YoY) | 15.60% | 9.80% | +5.80 | DXCM | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.87% | -0.87 | RMD | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 7.14 | 12.49 | -5.35 | RMD | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 9/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 41.8 | 60.1 | -18.30 | RMD | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.10 | 0.93 | +0.17 | DXCM | /macro-sensitivity <GO> |
| Forward P/E Multiple | 30.3x | 23.6x | +6.70 | RMD | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $30.16B | $35.56B | -$5.40B | RMD | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | DXCM REV | RMD REV | DXCM GROSS % | RMD GROSS % | DXCM FCF | RMD FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $4.66B | $5.15B | 60.1% | 59.4% | $1.08B | $1.66B |
| FY 2024 | $4.03B | $4.69B | 60.5% | 56.7% | $630.7M | $1.30B |
| FY 2023 | $3.62B | $4.22B | — | — | $585.5M | $503.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
DXCM // BETA 1.10
RMD // BETA 0.93